News & Events

News &
Events

Dosing Of First Patient In GADOT 20/20 Trial, A Phase I/IIa Study Of TRS01 In Patients With Non-Infectious Anterior Uveitis

Feb. 04, 2020

TRS is a first-in-class investigational product for the treatment of blinding ocular diseases

TTEL AVIV, Israel, February 4th, 2020 — Tarsius Pharma Ltd, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases today announced the initiation of dosing in its GADOT 20/20 Trial. The GADOT 20/20 Trial is a randomized, double-masked, dose-ranging Phase I/IIa study to evaluate the safety and tolerability of TRS01 eye drops in participants with Active Non-infectious Anterior Uveitis. The trial is expected to enroll approximately 10 patients with non-infectious anterior uveitis and top-line results from this USA proof-of-concept trial are expected by the end of 2020. Dr. Daphne Haim-Langford, Tarsius’ Founder and CEO, stated, “it is a great privilege for me personally to be able to bring the novel TRS to patients struggling with uveitis. I hope for the patients’ prompt and full recovery” “This is a new promising chemical entity that gives real promise of efficacy and safety to patients with anterior non-infectious uveitis. We hope that TRS will provide the appropriate option of non-steroid topical treatment for uveitis for patients who cannot tolerate steroids and their immense burden of adverse events. Once successful, this is expected to revolutionize the way we think about and treat ocular inflammatory diseases” stated Dr. Ron Neumann, Tarsius CMO.

About Ocular Inflammatory Diseases

Ocular inflammatory diseases impose a significant medical and economic burden on society, affecting hundreds of million people worldwide and posing severe risks of vision loss and blindness.

In more than 50 years, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in life-changing consequences.

The TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases.

About the Company

Tarsius Pharma was established in 2016 and is focused on developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases.

The company’s investors include Sun Pharmaceuticals, a global pharmaceutical company, BioLight Life Sciences Ltd, as well as private investors and family offices. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 879598.  

For more information please contact:
info@tarsiuspharma.com
Tel: +1-914-3392556
http://www.tarsiuspharma.com

Scroll to Top
Skip to content